Drug intelligence / Profile preview

Compound 386

Development stage
Preclinical
Lead developer
Shuguang Hospital
Administration
Oral
01

Overview

**Compound 386** is an investigational traditional Chinese multi-herb formula, also called Nourishing Liver and Kidney Compound 386, being developed by Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine and Shanghai University of Traditional Chinese Medicine for hepatitis B virus-related decompensated cirrhosis. The formula is derived from *Xu Ming Yi Lei An* and publicly reported components include rehmannia root, glehnia root, ophiopogon root, and angelica root. It is being evaluated as Compound 386 granules in a randomized, double-blind, placebo-controlled, multicenter clinical study, alongside antiviral therapy, with overall survival and safety as principal objectives. ([chictr.org.cn](https://www.chictr.org.cn/showproj.html?proj=201447))

Other names
Compound 386Compound386Compound-386Compound 386 granulesCompound386 granulesCompound-386 granulesNourishing Liver and Kidney Compound 386复方386复方386颗粒滋养肝肾复方386
02

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on Compound 386.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Compound 386.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call